We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

8593:TSEMitsubishi HC Capital Inc. Analysis

Data as of 2026-07-26 - not real-time

¥1,439.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Mitsubishi HC Capital is trading at ¥1,439, just shy of its technical resistance of ¥1,444, while the 14‑day RSI sits at a lofty 68.7, indicating near‑overbought conditions. The MACD remains bullish (histogram +7.1) and the 20‑day SMA (¥1,378) is comfortably below the current price, supporting the short‑term upside bias, yet the price‑to‑earnings multiple of 12.8 is well below the industry average of 17.8, suggesting a valuation edge.
However, the balance sheet raises red flags: a debt‑to‑equity ratio of nearly 500× and a massive operating cash‑flow deficit of ¥367 bn offset a modest free‑cash‑flow surplus, casting doubt on the sustainability of the 3.6% dividend (payout ratio ~41%). Low beta (0.14) and stable volume temper market‑risk concerns, but 30‑day volatility of 17.4% and a max drawdown of –18% highlight price sensitivity. Overall, the stock offers attractive yield and relative cheapness but is weighed down by leverage and cash‑flow weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just below resistance at ¥1,444
  • High RSI (68.7) indicating overbought pressure
  • Bullish MACD supporting limited upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • PE well below industry average, implying valuation upside
  • Attractive dividend yield of 3.6% with reasonable payout ratio
  • Low beta and stable trading volume suggest steady market support

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Extremely high debt‑to‑equity ratio limiting financial flexibility
  • Negative operating cash flow raises sustainability concerns
  • Diversified global footprint mitigates single‑region exposure

Key Metrics & Analysis

Financial Health

Revenue Growth3.10%
Profit Margin7.32%
P/E Ratio12.8
ROE8.54%
ROA1.21%
Debt/Equity493.99
P/B Ratio1.0
Op. Cash Flow¥-367536996352
Free Cash Flow¥1.9B
Industry P/E17.8

Technical Analysis

TrendNeutral
RSI68.7
Support¥1,301.00
Resistance¥1,444.00
MA 20¥1,377.75
MA 50¥1,338.24
MA 200¥1,343.08
MACDBullish
VolumeStable
Fear & Greed Index88.25

Valuation

Target Price¥1,408.33
Upside/Downside-2.13%
GradeUndervalued
TypeValue
Dividend Yield3.61%

Risk Assessment

Beta0.14
Volatility17.41%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.